製品名:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

IUPAC Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

CAS番号:916420-27-4
分子式:C12H15Cl2N3O2
純度:95%+
カタログ番号:CM104183
分子量:304.17

包装単位 有効在庫 価格(USD) 数量
CM104183-5g in stock ŢȎ
CM104183-10g in stock NJʼnNJ
CM104183-25g in stock ĽưĽ
CM104183-100g in stock ǯƄƞ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:916420-27-4
分子式:C12H15Cl2N3O2
融点:-
SMILESコード:CC(C)(C)OC(=O)N1CCC2=C(Cl)N=C(Cl)N=C2C1
密度:
カタログ番号:CM104183
分子量:304.17
沸点:
MDL番号:MFCD09025732
保管方法:

Category Infos

Column Infos

Adagrasib
Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.

Related Products